More on BIOA
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.16 |
|
|||
| Open | $46.41 | ||||
| 52 Wk High | $8.73 | ||||
| 52 Wk Low | $2.86 | ||||
| Day High | $0.16 | ||||
| Day Low | $0.16 | ||||
| P/E | N/A | ||||
| EPS | $-3.82 | ||||
| Volume | 1,375,961 | ||||
- Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
- BioArctic and Eisai sign research evaluation agreement regarding BAN2802
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
- Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
- BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease
- BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress
- BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
- The European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
- Leqembi® approved for the treatment of Alzheimer's disease in China
Entities mentioned with BIOA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- PDUFA | View Related Stories »
- IPO | View Related Stories »
- 13G | View Related Stories »
- Raymond James | View Related Stories »
- Show More...
